ClinicalTrials.gg
Active, not recruitingNCT07628088AtheroscopeUpdated Jun 10, 2026

AI-THEROSCOPE: AI Detection of Subclinical Atherosclerosis From Retinal Images

An observational study in Subclinical Atherosclerosis and Cardiovascular Risk, sponsored by Infanta Leonor University Hospital. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Infanta Leonor University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
884
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Atherosclerosis with a site in Spain — 10 open to participants now, 25 under way, 12 of them phase 3. Atherosclerosis · Spain.

Planned enrollment
8th of 20
884 · median 255
Started
2023
with 1 other
Observational
20 of 61
3 open now
Primary completion
2026-01
later than 2 of 24 live
Registered
59th of 61
by date

Among the 61 studies in Atherosclerosis with a site in Spain, this one is the 8th largest by planned enrollment of the 20 observational ones that give a count, is one of 2 that started in 2023, is one of 20 observational ones, reaches primary completion later than 2 of the 24 other live ones, and was the 59th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

10 of the 61 studies in Atherosclerosis with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Atherosclerosis with a site in Spain, or all of them as a file.
02

Study summary

Cardiovascular risk scores are widely used for risk stratification but may fail to identify a substantial proportion of individuals with subclinical atherosclerosis who are at increased risk of future cardiovascular events. Vascular ultrasound can directly detect carotid and femoral atherosclerotic plaques but its implementation is limited by the need for trained operators and expert interpretation. The AI-THEROSCOPE study aims to develop and validate an artificial intelligence-based tool capable of detecting subclinical atherosclerosis through the analysis of non-mydriatic retinal fundus images. Participants undergo clinical assessment, laboratory testing, carotid and femoral ultrasound, and retinal fundus photography. The performance of the AI model will be evaluated against vascular ultrasound findings as the reference standard for the presence of subclinical atherosclerosis.

Read the detailed description

Cardiovascular disease remains the leading cause of mortality worldwide. Current cardiovascular risk prediction models are useful for population-level risk estimation but may underestimate risk in a substantial proportion of individuals who already have subclinical atherosclerosis. Vascular ultrasound of the carotid and femoral arteries allows direct visualization of atherosclerotic plaques and improves cardiovascular risk stratification, but its widespread use is limited by the requirement for specialized equipment and trained personnel.

Retinal fundus imaging provides a non-invasive assessment of the microvasculature and has emerged as a promising tool for cardiovascular risk evaluation. Recent advances in artificial intelligence and deep learning have demonstrated the ability of retinal image analysis to identify cardiovascular risk factors and predict cardiovascular outcomes.

The AI-THEROSCOPE study is a prospective observational study designed to develop and validate an artificial intelligence model for the detection of subclinical atherosclerosis using non-mydriatic retinal fundus photographs. Adult participants without previous cardiovascular disease undergo standardized clinical evaluation, laboratory testing, carotid and femoral vascular ultrasound, and bilateral retinal fundus photography.

The presence of carotid and/or femoral atherosclerotic plaque assessed by vascular ultrasound serves as the reference standard. Deep learning techniques will be used to train and validate predictive models based on retinal images. Model performance will be evaluated using discrimination metrics including the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value, and negative predictive value.

The ultimate objective of the project is to develop a scalable, non-invasive, and easily deployable tool that may facilitate early detection of subclinical atherosclerosis and improve cardiovascular risk stratification in clinical practice and population screening programs.

03

Conditions studied

  • Subclinical Atherosclerosis
  • Cardiovascular Risk

Browse trials for

Keywords

  • Artificial Intelligence
  • Deep Learning
  • Retinal Imaging
  • Non-Mydriatic Fundus Camera
  • Carotid Plaque
  • Femoral Plaque
  • Subclinical Atherosclerosis
  • Oculomics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults undergoing cardiovascular risk assessment at a university hospital cardiovascular risk unit and healthcare workers or relatives participating in cardiovascular screening programs. All participants undergo clinical evaluation, laboratory testing, carotid and femoral vascular ultrasound, and non-mydriatic retinal fundus photography.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • No previous established cardiovascular disease.
  • Undergoing cardiovascular risk assessment and carotid and femoral vascular ultrasound.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Previous acute coronary syndrome, stroke, or peripheral arterial disease.
  • Previous carotid or femoral vascular surgery or stenting.
  • Previous ophthalmologic surgery.
  • Retinal or ocular diseases that significantly affect retinal vasculature or image quality, including moderate or severe diabetic retinopathy, retinal vascular occlusion, advanced hypertensive retinopathy, exudative age-related macular degeneration, or macular edema.
  • Inability or unwillingness to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
884 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants Undergoing Retinal Imaging and Vascular Ultrasound

    Adult participants without previous established cardiovascular disease who undergo standardized cardiovascular risk assessment, laboratory testing, bilateral carotid and femoral vascular ultrasound, and non-mydriatic retinal fundus photography. The cohort is used for the development and validation of an artificial intelligence model for the detection of subclinical atherosclerosis using retinal fundus images. The presence of carotid and/or femoral atherosclerotic plaque assessed by vascular ultrasound serves as the reference standard.

06

What researchers measure

Primary outcomes

  1. Area Under the Receiver Operating Characteristic Curve (AUC) for Detection of Subclinical Atherosclerosis

    Diagnostic performance of the artificial intelligence model based on non-mydriatic retinal fundus images for detecting carotid and/or femoral atherosclerotic plaques, using vascular ultrasound as the reference standard.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be publicly shared. De-identified data may be made available upon reasonable request to the principal investigator, subject to institutional policies, ethical approval, data protection regulations, and applicable legal requirements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jan 2026, 27 months.

Of 145 non-industry observational studies under Atherosclerosis, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 158. This study's 27 months is below that.

Counting every sponsor, half of 170 studies reached it within 62 months; a quarter within 31 and three quarters within 153.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 4, 2026
StartActual
Oct 1, 2023
Primary completionActual
Jan 1, 2026
CompletionEst.
Jan 1, 2028
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07628088
Lead sponsor
Infanta Leonor University Hospital
Responsible party
Anabel Franco Moreno (Specialist in Internal Medicine, Infanta Leonor University Hospital) — Principal investigator
First posted
Jun 4, 2026
Start date
Oct 1, 2023
Primary completion
Jan 1, 2026
Completion
Jan 1, 2028 (estimated)
Last update
Jun 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion